Feasibility of Capecitabine Immunotherapy in a Taxane-Refractory Metastatic Breast Cancer Patient: A Rural Cancer Hospital Experience

Oncology, Gastroenterology and Hepatology Reports,2013,2,2,23-26.
Published:July 2013
Type:Original Article
Author(s) affiliations:

Vivek Tiwari, Piyush Shukla,1 Gourav Gupta2

Department of Radiation Oncology, MIMS, Village Mirpur, Rewari, (HR)

1AIIMS, 2RGCI and RC, Delhi, India


To manage a metastatic cancer patient in a rural setting is a daunting task owing to the lack of resources and infrastructure. Intravenous chemotherapy (CT), with its debilitating side effects, often causes a decrease in the quality of life (QOL) of the patient. When the treatment is of palliative intent, efforts should be made to provide maximum symptom relief to the patient, striking a balance between the patient’s wishes and a sound scientific rationale. We describe our experience with a patient with extensively metastatic breast cancer treated in our rural center with single-agent oral capecitabine, without development of any severe toxicity and with a significant improvement in disease process and patient’s performance status (PS).